CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Denosumab

Last Updated: June 6, 2011
Result type: Reports
Project Number: S0235
Product Line: Common Drug Review

Generic Name: Denosumab

Brand Name: XGEVA

Manufacturer: Amgen Canada Inc.

Indications: Prevention of skeletal-related events due to bone metastases from solid tumours

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: November 16, 2011

Recommendation Type: List with clinical criteria and/or conditions